Celularity Inc. Confirms Nasdaq Compliance
Celularity Inc., a pioneer in regenerative medicine, recently received confirmation from the Nasdaq Stock Market that it has restored compliance with Nasdaq Listing Rule 5250(c)(1). This development comes after the successful filing of its Quarterly Report on Form 10-Q for the period ending September 30, 2024, which officially closes the compliance matter and secures its status on the Nasdaq Capital Market.
Leadership's Perspective on Compliance
Robert J. Hariri, the Founder and CEO of Celularity, expressed satisfaction with the resolution, emphasizing the importance of adhering to Nasdaq's requirements to maintain public trust and market integrity. He remarked, "This milestone reflects our commitment to regulatory compliance and transparency. The significant improvements we’ve made to our financial reporting infrastructure will serve as a strong foundation for our future growth and success."
Addressing Filing Delays
Celularity faced delays in its filings, primarily due to a necessary focus on clearing a backlog of reporting requirements for the prior periods. The company has taken substantial steps to enhance its financial management processes, including appointing EisnerAmper LLP as its independent auditor and strengthening internal controls to avoid future delays.
Dr. Hariri added, "We are confident in the steps we’ve taken to strengthen our finance function and ensure timely and accurate reporting going forward. This resolution marks a critical turning point for Celularity as we continue advancing our mission to harness the potential of the placenta to develop transformative therapies."
About Celularity Inc.
Celularity Inc. is making significant strides in the field of regenerative medicine. The company is focused on developing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies. By utilizing technologies such as mesenchymal-like adherent stromal cells (MLASCs) and CAR T-cells, Celularity aims to tackle pressing health issues related to aging, cancer, and immune disorders.
Innovative Therapies Derived from Placenta
What sets Celularity apart is its commitment to harnessing the placental biology to create new therapeutic solutions for unmet medical needs. The placental-derived therapies promise potential treatments that are both effective and accessible to a broader population, addressing significant gaps in existing treatment methodologies.
Future Growth and Innovations
Celularity's commitment to developing innovative treatments is underpinned by its strong belief in continuous improvement and adaptation within its finance and operational frameworks. This resolute approach positions the company favorably for future growth and allows it to potentially lead in the competitive regenerative medicine landscape.
Frequently Asked Questions
What does Nasdaq compliance mean for Celularity Inc.?
Nazdaq compliance confirms that Celularity Inc. meets the necessary financial and operational standards required to maintain its listing on the Nasdaq, enabling it to continue trading publicly.
What were the reasons for the filing delays?
The filing delays were attributed to challenges related to a backlog of financial reporting, including necessary filings for previous quarters, which the company has now addressed.
What has Celularity done to improve its financial reporting?
Celularity has implemented significant process improvements, including the hiring of EisnerAmper LLP as its independent audit firm and enhancing its internal controls for better accuracy and timeliness.
What are Celularity's key therapeutic targets?
Celularity focuses on developing therapies for aging-related diseases, cancer, and other immune disorders using advanced placental-derived technologies.
How does Celularity plan to ensure future compliance?
Celularity is committed to maintaining regulatory compliance through strengthened internal processes and timely reporting capabilities. The leadership team is dedicated to transparency and adherence to Nasdaq standards.
